Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Houston, TX
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Seattle, WA
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
mi
from
Montreal,
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
mi
from
Montreal,
Click here to add this to my saved trials
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Chicago, IL
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Maywood, IL
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Maywood, IL
Click here to add this to my saved trials
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Boston, MA
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Detroit, MI
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Minneapolis, MN
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Cleveland, OH
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Charleston, SC
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Memphis, TN
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Dallas, TX
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated:  8/1/2016
mi
from
Darlinghurst,
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status: Enrolling
Updated: 8/1/2016
mi
from
Darlinghurst,
Click here to add this to my saved trials
Patient-Reported Preferences Affecting Revascularization Decisions
Patient-Reported Preferences Affecting Revascularization Decisions
Status: Enrolling
Updated:  8/2/2016
Duke University Hospital
mi
from
Durham, NC
Patient-Reported Preferences Affecting Revascularization Decisions
Patient-Reported Preferences Affecting Revascularization Decisions
Status: Enrolling
Updated: 8/2/2016
Duke University Hospital
mi
from
Durham, NC
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Birmingham, AL
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Northport, AL
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Northport, AL
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Phoenix, AZ
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Tucson, AZ
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Spring Valley, CA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Spring Valley, CA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Torrance, CA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Torrance, CA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Walnut Creek, CA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Fort Lauderdale, FL
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Jacksonville, FL
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Pembroke Pines, FL
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Chicago, IL
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Indianapolis, IN
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Lacombe, LA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Lacombe, LA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Slidell, LA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Slidell, LA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Auburn, ME
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Auburn, ME
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
New York, NY
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Statesville, NC
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Statesville, NC
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Cincinnati, OH
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Oklahoma City, OK
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Camp Hill, PA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Camp Hill, PA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Philadelphia, PA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Bryan, TX
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Bryan, TX
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Houston, TX
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
San Antonio, TX
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Salt Lake City, UT
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Norfolk, VA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Richmond, VA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Buenos Aires,
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Buenos Aires,
Click here to add this to my saved trials
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Status: Enrolling
Updated:  8/4/2016
Northwestern Medical Center
mi
from
Chicago, IL
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Status: Enrolling
Updated: 8/4/2016
Northwestern Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Status: Enrolling
Updated:  8/4/2016
Indiana University Health
mi
from
Indianapolis, IN
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Status: Enrolling
Updated: 8/4/2016
Indiana University Health
mi
from
Indianapolis, IN
Click here to add this to my saved trials
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Status: Enrolling
Updated:  8/4/2016
University of Iowa
mi
from
Iowa City, IA
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Status: Enrolling
Updated: 8/4/2016
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Status: Enrolling
Updated:  8/4/2016
Brigham and Woman's Hospital
mi
from
Boston, MA
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Status: Enrolling
Updated: 8/4/2016
Brigham and Woman's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Status: Enrolling
Updated:  8/4/2016
Massachusetts General Hospital
mi
from
Boston, MA
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Status: Enrolling
Updated: 8/4/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Status: Enrolling
Updated:  8/4/2016
Moses Cone Memorial Hospital
mi
from
Greensboro, NC
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Status: Enrolling
Updated: 8/4/2016
Moses Cone Memorial Hospital
mi
from
Greensboro, NC
Click here to add this to my saved trials